Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

--Initiative Creates Groundbreaking New, Royalty Free Inclusive Image Gallery In Strategic Partnership with Shutterstock Studios-- IRVINE, Calif. and PHOENIX , Sept.

The Forces of Beauty® Report from The DREAM Initiative® Reveals Demand for New Standards of Beauty and Imagery

Aflac

Cardinal Health

Essex Property Trust

General Dynamics

Walmart

Exxon Mobil

In what will be known in the future as the pandemic years, the easy money and the government's spoon-fed liquidity made lots of new investors feel like they were genius and savvy traders.

Stock Market Could Plunge: These 7 Dividend Aristocrats Can Survive the Fall

The CHMP recommends authorizing AbbVie's (SNY) Skyrizi as a treatment for Crohn's disease. The drug is approved for treating plaque psoriasis and psoriatic arthritis indications.

AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication

AbbVie has a small hurdle to overcome the impact of the LOE on key drug Humira. The company remains on path for a nearly $12 EPS stream at the low point in 2023 and 2024.

AbbVie: Small Hurdle

AbbVie is a global biopharmaceutical company with a vast portfolio of drugs and therapies. Its blockbuster drug, Humira, is set to lose exclusivity in 2023.

AbbVie: Valuation Attractive Due To Humira Headwinds

Pfizer

There are attractive income stocks in the healthcare space. Both ABBV and PFE offer compelling yields and regular dividend growth. Both companies will likely have a down year in 2023, but not to the same extent.

Better High-Yield Pick: AbbVie Vs. Pfizer

-  CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance1,2 -  Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea, abdominal pain and can require urgent medical care3,4 -  If approved, risankizumab will be the first specific IL-23 inhibitor for the treatment of Crohn's disease in the European Union (EU) -  The European Commission decision is expected in the fourth quarter of 2022. This anticipated approval would mark the third indication for risankizumab in the EU NORTH CHICAGO, Ill.

AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn's Disease

Bristol-Myers

Forbes is tracking the biggest layoffs in the U.S. this summer as companies react to fears of a looming recession.

Calif. Pharmaceutical Companies AbbVie And Bristol Myers Lay Off 360—Here Are The Major U.S. Layoffs This Summer

Drugmakers Bristol Myers Squibb Co and AbbVie Inc told California officials that they plan to cut up to 360 jobs there in unrelated moves, according to notices filed with the state that were made public earlier this week.

Bristol Myers, AbbVie plan to cut up to 360 California jobs

AstraZeneca

Merck

Novartis

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.

4 Large Drug Stocks to Watch as Fundamentals Stay Strong

Amgen

Makers of the top selling drugs in the United States are costing patients billions of dollars and worsening a drug pricing crisis by abusing the U.S. patent system to stifle competition and inflate prices, a consumer group said on Thursday,

Consumer group says drugmakers abuse U.S. patent system to keep prices high

AbbVie has delivered strong earnings over recent quarters. The total return on ABBV over the past year is 36.6%.

Outlook For AbbVie Continues To Look Favorable

ADMA Biologics

Geron

Prometheus Biosciences

SIGA Technologies

Voyager Therapeutics

Axsome Therapeutics

A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

7 Top-Rated Biotech Stocks to Buy for Q4

--Results will be presented from the Phase 3 M15-736 trial, a randomized, double-blind, double-dummy, active-controlled study, evaluating the continuous subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) in people with advanced Parkinson's disease --Data will also be presented on real-world efficacy of BOTOX® (onabotulinumtoxinA) for the treatment of spasticity and BOTOX® for the treatment of cervical dystonia --Research highlights AbbVie's continued commitment to advancing the management of movement disorders NORTH CHICAGO, Ill. , Sept. 15, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data from its robust neuroscience portfolio will be presented at the 2022 International Parkinson and Movement Disorder Society's (MDS) International Congress, taking place in Madrid, Spain, from September 15-18.

AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Congress

AbbVie Inc. (NYSE:ABBV ) Morgan Stanley 20th Annual Global Healthcare Conference September 13, 2022 10:35 AM ET Company Participants Rob Michael - Vice Chairman and President Jeff Stewart - Executive Vice President and Chief Commercial Officer Neil Gallagher - Vice President, Development and Chief Medical Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Well, thanks everybody for joining us.

AbbVie Inc.'s (ABBV) Management Presents at Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)

Online and mobile voting is open to the public now through September 28 to help determine this year's two Thriving Scholars Forty students living with cystic fibrosis (CF) are in the running for the two $25,000 awards based on their academic excellence, creativity, and community involvement/extracurricular activities This year's scholarship program marks 30 years of AbbVie's commitment to students with CF pursuing higher education NORTH CHICAGO, Ill. , Sept. 14, 2022 /PRNewswire/ -- AbbVie today announced the start of its two-week public voting period for the 2022 Thriving Undergraduate and Graduate Scholarships.

AbbVie Announces Public Voting Open for 30th Annual Cystic Fibrosis Scholarship "Thriving Student Awards"

AbbVie Inc (NYSE: ABBV) is a better long-term investment than peer Bristol-Myers Squibb Co (NYSE: BMY) even though the latter just secured FDA approval for its Psoriasis pill, says Mohit Bansal. He's a Managing Director at Wells Fargo.

Bristol-Myers versus AbbVie stock: Expert picks a side

NEARLY 20,000 PEOPLE RESPONDED TO AN OPEN CASTING CALL FOR A CHANCE TO BE FEATURED IN THE UPCOMING CAMPAIGN FOR THE NUMBER ONE SELLING PRODUCT OF ITS KIND IRVINE, Calif. , Sept. 13, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is unveiling the 25 real patients – of all forms, genders, ethnicities and backgrounds – who were selected to participate in the latest iteration of the BOTOX® Cosmetic 'See Yourself' campaign.

Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories

Abbott Labs

Gilead Sciences

These stocks offer more than just dividends.

3 Unstoppable Dividend Stocks to Buy in September

This pair of Midwestern companies have outperformed in recent years, and their futures look brighter than ever.

2 Dividend Aristocrats to Buy for Passive Income That Could Outperform the Market

Amcor Plc

Air Products and Chemicals

Franklin Resources

Caterpillar

Federal Realty Investment Trust

Leggett & Platt

Medtronic

Realty Income Corp

Stanley Black & Decker

T. Rowe Price Group

V.F.

Walgreens

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 65 Aristocrats screened as of September 8, 2022 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 16.54%-36.34% topped by VFC & SWK.

4 S&P 500 Dividend Aristocrat Dogs To Buy, 1 To Watch

Biogen

Is now a good time to add these biotech stocks to your watchlist?

Best Stocks To Buy Now? 4 Biotech Stocks In Focus

- Analyses included 100-week efficacy and safety data from the four-year, open-label extension period of KEEPsAKE 1 and 2 evaluating SKYRIZI in patients with active psoriatic arthritis1 - Ongoing treatment with SKYRIZI demonstrated consistent long-term efficacy in psoriatic arthritis with similar rates of improvement in skin (PASI 90) and joint (ACR, enthesitis, dactylitis) symptoms at week 100 as those reported at week 521 - No new safety signals were observed through 100 weeks1-4 NORTH CHICAGO, Ill. , Sept. 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI® (risankizumab, 150 mg) in adult patients with active psoriatic arthritis.

New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100

Crown Castle International

Costco

Chevron

Goldman Sachs

PepsiCo

Waste Management

Starting the session following Labor Day weekend in the red, it's clear that even so-called S&P 500 stocks to buy are feeling the heat. Toward the end of August, Federal Reserve chair Jerome Powell presented a less-than-encouraging picture for future monetary policy.

7 S&P 500 Stocks to Buy With Superior Fundamentals

MEASURE-AD was a real-world study of moderate to severe atopic dermatitis patients across 28 countries designed to assess the multidimensional burdens that diagnosed patients face1-3 Additional findings show that lower clinical burden and work impairment had a positive association with quality of life and lower disease severity scores1 Atopic dermatitis, also known as eczema, impacts up to an estimated 10 percent of adults and 25 percent of children globally and causes significant physical, psychological and economic impact4-7 NORTH CHICAGO, Ill. , Sept. 8, 2022 /PRNewswire/ -- An analysis from AbbVie's (NYSE: ABBV) three-year, 28-country MEASURE-AD study revealed that people living with moderate to severe atopic dermatitis (an immune-mediated skin disease) who are not receiving systemic therapy had greater clinical, psychosocial and economic burdens compared to those receiving systemic therapy.1 A separate analysis from the MEASURE-AD study demonstrated that better quality of life – as measured by Dermatology Life Quality Index (DLQI) scores – and lower disease severity scores were associated with lower clinical burden and work impairment.2 Results from the MEASURE-AD subanalyses were featured at the 31st European Academy of Dermatology and Venereology (EADV) Hybrid Congress onsite in Milan and online from September 7-10 as a poster and an oral presentation.

News for AbbVie Stock (ABBV)